bitBiome can contribute to the diverse R&D needs of our customers
with our professionals in each field using next-generation microbiome analysis.



Co-Founder/President, CEO

Yoshihito Daimon graduated from microbial technology and genetic resources engineering at Kyushu University Graduate School and engaged in intellectual property (IP) and legal at Astellas Pharma Inc.
Then he transferred to Astellas US and was in charge of M&A and many alliances. In IP litigations in a pharmaceutical field, he has engaged in 12 trials with 12 wins and 0 loss and contributed to the business to produce profits of over 10 billion yen through his outstanding skills related to pharmaceutical legal and IP strategies.
In recent years, he has been working as a founding supporter who helps many life-sciences startups from the perspective of legal and IP strategies. He has been voluntarily supporting IPAS (IP Acceleration program for Startups) by the Japan Patent Office and Pharmaceutical & Medical Startup Acceleration Program supported by the Tokyo Metropolitan Government as Legal/IP mentor.
He also works as a specially appointed professor in Tohoku University Head Office for Open Innovation Strategy.


Founder/Director, CSO

Masahito Hosokawa received his Ph.D. in Engineering from Tokyo University of Agriculture and Technology in 2010.
After a postdoctoral training at Shizuoka cancer center between 2011 and 2013, he moved to Waseda University in 2013 and started single-cell researches as a JST-PRESTO researcher in 2015.
His research is interested in developing and applying novel microfluidic tools for single-cell genomics and transcriptomics. He founded bitBiome Inc. in 2018 based on his single-cell genomics platform. Major awards include The Young Scientists’ Prize by Minister of Education, Culture, Sports, Science and Technology (2019) and the JST PRESTO Innovation Award (2019).
He also works as an Assistant Professor in Waseda University.



Sunao Fujioka obtained his master's degree in pharmaceutical sciences at the University of Tokyo. He started his career at McKinsey & Company Japan office, then moved to Janssen Pharmaceuticals, and most recently at MSD, mainly in charge of marketing / business operations.
At MSD, he has led launch of the biomarker / diagnostic field in the oncology business, developed and accelerated novel biomarkers / companion diagnostic adoption in Japan market with relevance to immune-checkpoint inhibitors, such as PD-L1, MSI, etc. He also has marketing experiences in vaccines, gynecologic cancers, breast cancers, and hematology.
He joined bitBiome Inc. from 2019.


External Director

Atsushi Usami studied pharmacology and neuroscience and received a Ph.D. In pharmaceutical sciences from the University of Tokyo and is a pharmacist. In pharmaceutical sciences from the University of Tokyo and is a pharmacist. He worked as a consultant at MRI before joining UTEC in October 2013.
He focuses on seed/early-stage life science investments. He currently serves on the boards of Repertoire Genesis Inc., Goryo Chemical Inc., EditForce Inc., MiRTel Co. Ltd., Epigeneron Inc., Bugworks Research Inc., and OriCiro Genomics, Inc. He is a JST START promotor and a NEDO TCP mentor. He helps with commercialization and teaches seminar on industry-academia collaboration at colloquiums in the Graduate Program for Leader in Life Innovation at the University of Tokyo. He provides support for Life Science Innovation network Japan (LINK-J).



Noriaki Sakamoto graduated from the Faculty of Economy from the University of Tokyo and entered METI. He left METI in 2008 and was appointed vice president of a logistics company. He earned MBA from Columbia University. He was an engagement manager at McKinsey & Company and then joined UTEC in August 2014.
He currently serves on the boards of Finatext Inc., Institution for a Global Society Corp., Retrieva, Inc., Neural Pocket Inc., JDSC Co., Liquid, Inc., and TRICOG HEALTH PTE. LTD. He has served as a corporate auditor of the Autonomous Control Systems Research Institute, Inc. / ACSL (listed on TSE Mothers in December 2018: 6232).